Here are the DEF 14A proxy statements from Cingulate Inc. Warrants (CINGW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CINGW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CINGW filings page.
Cingulate Inc. is asking stockholders to approve several items at its July 9, 2026 virtual annual meeting. Investors will vote on electing Jeff Hargroves as a Class II director through 2029, ratifying KPMG LLP as auditor for 2026, and expanding the 2021 Omnibus Equity Incentive Plan by 625,000 shares to a total of 2,221,126 shares. They will also consider an adjournment proposal to allow additional proxy solicitation if needed. The record date is May 18, 2026, when 13,469,036 common shares were outstanding, and detailed disclosures cover board structure, independence, committee work, executive employment terms, and 2025 compensation.
Cingulate Inc. is holding a virtual special stockholder meeting on March 24, 2026 to vote on approving the issuance of common stock tied to a recent private financing and on a possible adjournment of the meeting if votes are insufficient.
The vote would allow conversion of 954 shares of 12% Series A convertible preferred stock and the exercise of a warrant for 1,869,415 common shares, following a $12.0 million private placement that also included 2,147,472 common shares. At a $5.04 conversion and exercise price, this could add about 189,286 conversion shares plus the warrant shares, totaling roughly 19.1% of post‑placement shares.
The lead investor group, managed by Falcon Creek, acquired 2,049,222 common shares, all preferred shares and most warrant shares in the deal and could own about 32.7% of common stock on an as‑converted basis, with the right to designate two of seven directors if stockholders approve the issuance. If the proposal fails, the preferred stock continues accruing 12% annual cumulative dividends and retains its liquidation preference, the warrants cannot be exercised, and the company must call additional meetings every three months until approval.
Cingulate Inc. is calling a virtual special meeting on September 25, 2025 to ask stockholders to approve issuing more than 20% of its outstanding common stock under a purchase agreement with Lincoln Park Capital Fund, LLC. This approval is needed to comply with Nasdaq Listing Rule 5635(d) so the company can sell additional shares beyond a 19.99% cap in a private financing.
Under the agreement, Lincoln Park has committed to buy up to $25.0 million of Cingulate common stock over 36 months, and has already received 120,424 commitment shares. As of August 1, 2025, Cingulate had 5,264,642 shares outstanding. The company plans to use any proceeds from sales to Lincoln Park mainly for regulatory approval and development, manufacturing and commercialization activities for CTx-1301, as well as working capital and general corporate purposes. Stockholders are also being asked to approve a potential adjournment of the meeting if more time is needed to gather votes.